Nrf2激活剂RS9抑制病理性眼血管生成和高通透性
本研究评估Nrf2激活剂BARD和RS9对VEGF诱导的人视网膜微血管内皮细胞迁移的作用,并在小鼠氧诱导视网膜病变模型和激光诱导的猴脉络膜新生血管模型中观察RS9的效果。结果显示RS9抑制视网膜新生血管、改善血管渗漏,可能成为以病理性血管生成和高通透性为特征的眼病治疗候选药物。
要点
- BARD和RS9均减少VEGF诱导的HRMECs迁移并显著增加Ho-1 mRNA,仅RS9显著增加Nqo-1 mRNA。
- RS9通过抑制VEGF表达、增加Nrf2、HO-1、PDGFR-β和紧密连接蛋白减少OIR小鼠视网膜新生血管。
- RS9在激光诱导CNV猴模型中显示减少CNV病变的趋势并改善血管渗漏。
核心结论
- Nrf2激活剂可能是以病理生理性血管生成和高通透性为特征的眼病治疗的候选药物。
研究设计与样本
- 体外研究评估BARD和RS9对VEGF诱导的人视网膜微血管内皮细胞迁移的作用。
- 小鼠单次注射BARD和RS9后测量视网膜Nrf2靶基因Ho-1和Nqo-1 mRNA表达。
- 使用小鼠氧诱导视网膜病变模型评估RS9抗视网膜血管生成的效果和机制。
- 使用激光诱导CNV猴模型评估RS9抗脉络膜新生血管的效果。
主要发现
- BARD和RS9均减少VEGF诱导的细胞迁移,并显著增加Ho-1 mRNA表达;仅RS9显著增加Nqo-1 mRNA。
- RS9通过抑制VEGF表达并增加Nrf2、HO-1、PDGFR-β和紧密连接蛋白,减少OIR小鼠视网膜新生血管。
- RS9在CNV猴模型中显示减少CNV病变的趋势,并改善血管渗漏。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ocular angiogenesis, including retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration, are closely related to oxidative stress. Many reports have shown that the cellular protective mechanism against oxidative stress and inflammatory response has nuclear factor-erythroid 2-related factor-2 (Nrf2) activity. The aim of this study was to investigate the effectiveness and mechanism of Nrf2 activation in treating the ocular diseases with abnormal vessels. METHODS: The effects of Nrf2 activators, bardoxolone methyl (BARD) and RS9, were evaluated against vascular endothelial growth factor (VEGF)-induced cell migration in human retinal microvascular endothelial cells (HRMECs). We measured the expression of the Nrf2 target genes, Ho-1 and Nqo-1 mRNA, in mouse retinas after a single injection of BARD and RS9. The effects and mechanisms of RS9 against retinal angiogenesis were evaluated using an oxygen-induced retinopathy (OIR) model in mice. Moreover, the effect of RS9 against choroidal neovascularization (CNV) was evaluated in a laser-induced CNV monkey model. RESULTS: Both BARD and RS9 decreased VEGF-induced cell migration, and significantly increased Ho-1 mRNA expression; however, only RS9 significantly increased Nqo-1 mRNA. RS9 decreased retinal neovascularization through suppressing VEGF expression and increasing Nrf2, HO-1, platelet-derived growth factor receptor (PDGFR)-β, and tight junction proteins in OIR murine retinas. Furthermore, RS9 showed a tendency toward decreasing CNV lesions, and improved vascular leakage in a CNV monkey model. CONCLUSIONS: These data indicate that a Nrf2 activator might be a candidate for treatment of ocular diseases characterized by pathophysiological angiogenesis and hyperpermeability.
引用
- Nakamura S, Noguchi T, Inoue Y, et al. Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability. Invest Ophthalmol Vis Sci. 2019. PMID: 31050722. doi:10.1167/iovs.18-25745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。